Cargando…
An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients
OBJECTIVES: We aimed to determine the effect of sodium glucose cotransporter 2 (SGLT2) inhibitor monotherapy on glycemic and other clinical laboratory parameters versus other antidiabetic medications or placebo therapy in patients with type 2 diabetes mellitus. In addition, we aimed to investigate t...
Autores principales: | Wang, Yaowen, Hu, Xueting, Liu, Xueying, Wang, Zengqi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956063/ https://www.ncbi.nlm.nih.gov/pubmed/27486328 http://dx.doi.org/10.2147/TCRM.S112236 |
Ejemplares similares
-
Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal
por: Gupta, Vishal, et al.
Publicado: (2017) -
The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
por: Patel, Dhiren K., et al.
Publicado: (2019) -
Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
por: Takata, Tomoaki, et al.
Publicado: (2021) -
Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2018) -
The association of sodium‐glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews
por: Pelletier, Ryan, et al.
Publicado: (2020)